A phase II open-label single arm trial of nivolumab ipilimumab and short-course radiotherapy in adults with newly diagnosed MGMT unmethylated glioblastoma
Brief description of study
If you have been diagnosed with a form of brain cancer called glioblastoma and you have not received any therapy for your tumor other than surgery, you may be qualified to participate in a study evaluating a short course of radiation therapy, a drug called nivolumab, and a drug called ipilimumab. The goal of this phase II study is to test whether the combination of these drugs causes any side effects.
Clinical Study Identifier: s17-00218
ClinicalTrials.gov Identifier: NCT03367715
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
